Analysts at Citi have drawn attention to two newly released retrospective studies that suggest GLP-1 receptor agonists - drugs widely prescribed for diabetes and weight loss - could have an impact on cancer outcomes. While the research does not prove a causal relationship, Citi said the repeated pattern across multiple tumor types merits further clinical investigation.
One of the analyses, conducted by researchers at the University of Pennsylvania, reviewed data on nearly 95,000 women. After controlling for variables such as age, body mass index, race, ethnicity and diabetes status, the study found that use of GLP-1 receptor agonists was associated with a statistically significant reduction in the incidence of breast cancer.
A separate Cleveland Clinic evaluation covered seven tumor types and reported that patients with prior exposure to GLP-1 drugs experienced reduced metastatic progression in several cancers, including non-small cell lung cancer, breast cancer, colorectal cancer and liver cancer. Citi highlighted the lung cancer results as particularly striking, noting that outcomes in that cohort compared favorably with findings from some dedicated oncology studies.
In addition to the clinical analyses, Citi pointed to genomic evidence linking higher expression of GLP-1 receptors within tumors to improved overall survival. The firm said this biological signal - which showed up most prominently in breast cancer patients - strengthens the possibility that the observed clinical associations reflect a true therapeutic effect rather than random variation.
Despite these encouraging signals, Citi emphasized the limitations of the current evidence base. Both the University of Pennsylvania and Cleveland Clinic studies are retrospective in design and therefore cannot establish causality. The analysts said randomized clinical trials will be required to determine whether GLP-1 receptor agonists directly improve cancer outcomes.
Citi also noted that neither Eli Lilly and Company nor Novo Nordisk is currently conducting oncology-specific trials of GLP-1 therapies. That gap in prospective research frames the key uncertainty around whether the observational associations will translate into proven clinical benefits.
Looking ahead, Citi suggested that oncology could emerge as a meaningful source of long-term growth for GLP-1 drugs if the preliminary signals hold up in randomized testing. The firm placed this potential opportunity alongside other emerging indications it is tracking, including substance-use disorders and certain mental health conditions.
Context for markets and health sectors
If future randomized trials validate a direct anti-cancer effect, the implications would touch several sectors. Pharmaceutical and biotechnology companies that develop or market GLP-1 receptor agonists could see new demand drivers, while oncology-focused service providers and clinical trial operators might experience increased activity. Health-care payers and providers would also face questions about treatment guidelines and cost-effectiveness if GLP-1 drugs acquire established cancer-related indications.